Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Rupatadine in Renal Impairment
NCT06708520Phase 1Recruiting
- Sponsor
- Noucor Health S.A.
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of rupatadine in allergic rhinitis (AR) and urticaria (4 arms), sponsored by Noucor Health S.A. Primary endpoints: Area Under Plasma Concentration-Time Curve from Time Zero to Last Timepoint at 12 days, Area Under Plasma Concentration-Time Curve from Time Zero to Infinity at 12 days and 11 more. Started Nov 2022; status: recruiting.
02
Drugs
rupatadine
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on NCT06708520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708520.